Concert Announces Clinical Advisory Board, New Medical Policies
Retrieved on:
水曜日, 5月 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine
NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.
Key Points:
- The newly formed board will advise Concert on its clinical laboratory content.
- "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
- Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
- Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.